ARTICLE | Clinical News
AHP begins Phase III with TSE-424
June 22, 2001 7:00 AM UTC
Wyeth-Ayerst, the pharmaceutical division of American Home Products (AHP), began a U.S. Phase III study of TSE-424, a selective estrogen receptor modulator (SERM) for osteoporosis and hormone replacem...